Thymic malignancies: Moving forward with new systemic treatments

Siesling, 2012, Rare thoracic cancers, including peritoneum mesothelioma, Eur J Cancer, 48, 949, 10.1016/j.ejca.2012.02.047 Engels, 2010, Epidemiology of thymoma and associated malignancies, J Thorac Oncol, 5, S260, 10.1097/JTO.0b013e3181f1f62d Kelly, 2011, Thymic malignancies: from clinical management to targeted therapies, J Clin Oncol, 29, 4820, 10.1200/JCO.2011.36.0487 Mariano, 2013, Thymoma: a population-based study of the management and outcomes for the province of British Columbia, J Thorac Oncol, 8, 109, 10.1097/JTO.0b013e318276241c de Jong, 2008, Thymic epithelial tumours: a population-based study of the incidence, diagnostic procedures and therapy, Eur J Cancer, 44, 123, 10.1016/j.ejca.2007.11.004 Detterbeck, 2011, A review of prognostic factors in thymic malignancies, J Thorac Oncol, 6, S1698, 10.1097/JTO.0b013e31821e7b12 Girard, 2012, Chemotherapy and targeted agents for thymic malignancies, Expert Rev Anticancer Ther, 12, 685, 10.1586/era.12.29 Okuma, 2015, Key components of chemotherapy for thymic malignancies: a systematic review and pooled analysis for anthracycline-, carboplatin- or cisplatin-based chemotherapy, J Cancer Res Clin Oncol, 141, 323, 10.1007/s00432-014-1800-6 Loehrer, 1994, Cisplatin plus doxorubicin plus cyclophosphamide in metastatic or recurrent thymoma: final results of an intergroup trial. The Eastern cooperative oncology group, Southwest oncology group, and Southeastern cancer study group, J Clin Oncol, 12, 1164, 10.1200/JCO.1994.12.6.1164 Menis, 2015, Pan-European survey on thymic malignancies: a collaboration of the EORTC lung cancer group (LCG) with the RYTHMIC network, J Thorac Oncol, 10, 449 Girard, 2015, ESMO guidelines committee. Thymic epithelial tumours: ESMO clinical practice guidelines for diagnosis, treatment and follow-up, Ann Oncol, 26, v40, 10.1093/annonc/mdv277 Liang, 2015, Pemetrexed in patients with thymic malignancies previously treated with chemotherapy, Lung Cancer, 87, 34, 10.1016/j.lungcan.2014.11.006 Loehrer, 2006, A phase II trial of pemetrexed in patients with recurrent thymoma or thymic carcinoma, ASCO Meeting Abstr, 24, 7079 Boutros, 2013, Oral etoposide in pretreated advanced thymoma and thymic carcinoma. A French experience, Lung Cancer, 80, 10.1016/S0169-5002(13)70334-9 Wakelee, 2015, Phase II trial of single agent amrubicin (A) in patients (pts) with previously treated advanced thymic malignancies (TM), ASCO Meeting Abstr, 33, 7580 Inoue, 2014, Phase II study of Amrubicin combined with carboplatin for thymic carcinoma and invasive thymoma: North Japan lung cancer group study 0803, J Thorac Oncol, 9, 1805, 10.1097/JTO.0000000000000362 Palmieri, 2014, Capecitabine plus gemcitabine in thymic epithelial tumors: final analysis of a phase II trial, Future Oncol, 10, 2141, 10.2217/fon.14.144 Girard, 2009, Comprehensive genomic analysis reveals clinically relevant molecular distinctions between thymic carcinomas and thymomas, Clin Cancer Res, 15, 6790, 10.1158/1078-0432.CCR-09-0644 Rajan, 2014, State of the art of genetic alterations in thymic epithelial tumors, J Thorac Oncol, 9, S131, 10.1097/JTO.0000000000000298 Petrini, 2014, A specific missense mutation in GTF2I occurs at high frequency in thymic epithelial tumors, Nat Genet, 46, 844, 10.1038/ng.3016 Gennatas, 2015, Validation of a specific missense GT2FI mutation in more indolent thymic epithelial tumours, J Thorac Oncol, 10 Wang, 2014, Mutations of epigenetic regulatory genes are common in thymic carcinomas, Sci Rep, 4, 7336, 10.1038/srep07336 Gökmen-Polar, 2013, A gene signature to determine metastatic behavior in thymomas, PLoS ONE, 8, e66047, 10.1371/journal.pone.0066047 Wheler, 2013, Thymoma patients treated in a phase I clinic at MD Anderson cancer center: responses to mTOR inhibitors and molecular analyses, Oncotarget, 4, 890, 10.18632/oncotarget.1015 Kossai, 2015, Antitumor activity in advanced cancer patients with thymic malignancies enrolled in early clinical drug development programs (phase I trials) at Gustave Roussy, Lung Cancer, 89, 306, 10.1016/j.lungcan.2015.06.014 Lopez-Chavez, 2015, Molecular profiling and targeted therapy for advanced thoracic malignancies: a biomarker-derived, multiarm, multihistology phase II basket trial, J Clin Oncol, 33, 1000, 10.1200/JCO.2014.58.2007 Pan, 2004, KIT (CD117) is frequently overexpressed in thymic carcinomas but is absent in thymomas, J Pathol, 202, 375, 10.1002/path.1514 Yoh, 2008, Mutational status of EGFR and KIT in thymoma and thymic carcinoma, Lung Cancer, 62, 316, 10.1016/j.lungcan.2008.03.013 Schirosi, 2012, Activating c-KIT mutations in a subset of thymic carcinoma and response to different c-KIT inhibitors, Ann Oncol, 23, 2409, 10.1093/annonc/mdr626 Palmieri, 2012, Imatinib mesylate in thymic epithelial malignancies, Cancer Chemother Pharmacol, 69, 309, 10.1007/s00280-011-1690-0 Giaccone, 2009, Imatinib mesylate in patients with WHO B3 thymomas and thymic carcinomas, J Thorac Oncol, 4, 1270, 10.1097/JTO.0b013e3181b6be57 Salter, 2008, Imatinib for the treatment of thymic carcinoma, ASCO Meeting Abstr, 26, 8116 Pagano, 2014, Sorafenib efficacy in thymic carcinomas seems not to require c-KIT or PDGFR-alpha mutations, Anticancer Res, 34, 5105 Catania, 2014, Antitumor activity of sorafenib and imatinib in a patient with thymic carcinoma harboring c-KIT exon 13 missense mutation K642E, Onco Targets Ther, 7, 697, 10.2147/OTT.S58902 Neuhaus, 2012, Long lasting efficacy of sorafenib in a heavily pretreated patient with thymic carcinoma, Target Oncol, 7, 247, 10.1007/s11523-012-0235-8 Dişel, 2011, Promising efficacy of sorafenib in a relapsed thymic carcinoma with C-KIT exon 11 deletion mutation, Lung Cancer, 71, 109, 10.1016/j.lungcan.2010.09.011 Girard, 2010, Thymic tumors: relevant molecular data in the clinic, J Thorac Oncol, 5, S291, 10.1097/JTO.0b013e3181f209b9 Mimae, 2012, Protein expression and gene copy number changes of receptor tyrosine kinase in thymomas and thymic carcinomas, Ann Oncol, 23, 3129, 10.1093/annonc/mds147 Suzuki, 2006, Expression and mutation statuses of epidermal growth factor receptor in thymic epithelial tumors, Jpn J Clin Oncol, 36, 351, 10.1093/jjco/hyl028 Ionescu, 2005, Protein expression and gene amplification of epidermal growth factor receptor in thymomas, Cancer, 103, 630, 10.1002/cncr.20811 Palmieri, 2007, Cetuximab is an active treatment of metastatic and chemorefractory thymoma, Front Biosci, 12, 757, 10.2741/2098 Farina, 2007, Response of thymoma to cetuximab, Lancet Oncol, 8, 449, 10.1016/S1470-2045(07)70141-9 Bedano, 2008, A phase II trial of erlotinib plus bevacizumab in patients with recurrent thymoma or thymic carcinoma, ASCO Meeting Abstr, 26, 19087 Kurup, 2005, Phase II study of gefitinib treatment in advanced thymic malignancies, ASCO Meeting Abstr, 23, 7068 Weissferdt, 2012, HER family receptor and ligand status in thymic carcinoma, Lung Cancer, 77, 515, 10.1016/j.lungcan.2012.05.108 Pan, 2003, Expression of apoptosis-related markers and HER-2/neu in thymic epithelial tumours, Histopathology, 43, 165, 10.1046/j.1365-2559.2003.01663.x Gadgeel, 2013, Phase I study evaluating the combination of lapatinib (a Her2/Neu and EGFR inhibitor) and everolimus (an mTOR inhibitor) in patients with advanced cancers: South West oncology group (SWOG) study S0528, Cancer Chemother Pharmacol, 72, 1089, 10.1007/s00280-013-2297-4 Moroney, 2012, Phase I study of the antiangiogenic antibody bevacizumab and the mTOR/hypoxia-inducible factor inhibitor temsirolimus combined with liposomal doxorubicin: tolerance and biological activity, Clin Cancer Res, 18, 5796, 10.1158/1078-0432.CCR-12-1158 Zucali, 2014, Phase II study of everolimus in patients with thymoma and thymic carcinoma previously treated with cisplatin-based chemotherapy, ASCO Meeting Abstr, 32, 7527 Girard, 2010, Insulin-like growth factor-1 receptor expression in thymic malignancies, J Thorac Oncol, 5, 1439, 10.1097/JTO.0b013e3181e392a8 Zucali, 2010, Insulin-like growth factor-1 receptor and phosphorylated AKT-serine 473 expression in 132 resected thymomas and thymic carcinomas, Cancer, 116, 4686, 10.1002/cncr.25367 Rajan, 2014, Cixutumumab for patients with recurrent or refractory advanced thymic epithelial tumours: a multicentre, open-label, phase 2 trial, Lancet Oncol, 15, 191, 10.1016/S1470-2045(13)70596-5 Steele, 2008, A phase 1 pharmacokinetic and pharmacodynamic study of the histone deacetylase inhibitor belinostat in patients with advanced solid tumors, Clin Cancer Res, 14, 804, 10.1158/1078-0432.CCR-07-1786 Giaccone, 2011, Phase II study of belinostat in patients with recurrent or refractory advanced thymic epithelial tumors, J Clin Oncol, 29, 2052, 10.1200/JCO.2010.32.4467 Thomas, 2014, A phase I/II trial of belinostat in combination with cisplatin, doxorubicin, and cyclophosphamide in thymic epithelial tumors: a clinical and translational study, Clin Cancer Res, 20, 5392, 10.1158/1078-0432.CCR-14-0968 Lattanzio, 2014, Thymic epithelial tumors express vascular endothelial growth factors and their receptors as potential targets of antiangiogenic therapy: a tissue micro array-based multicenter study, Lung Cancer, 85, 191, 10.1016/j.lungcan.2014.05.010 Cimpean, 2008, Immunohistochemical expression of vascular endothelial growth factor A (VEGF), and its receptors (VEGFR1, 2) in normal and pathologic conditions of the human thymus, Ann Anat, 190, 238, 10.1016/j.aanat.2007.05.003 Sasaki, 2001, Elevated serum vascular endothelial growth factor and basic fibroblast growth factor levels in patients with thymic epithelial neoplasms, Surg Today, 31, 1038, 10.1007/s005950170021 Tomita, 2002, Correlation between tumor angiogenesis and invasiveness in thymic epithelial tumors, J Thorac Cardiovasc Surg, 124, 493, 10.1067/mtc.2002.124389 Thomas, 2015, Sunitinib in patients with chemotherapy-refractory thymoma and thymic carcinoma: an open-label phase 2 trial, Lancet Oncol, 16, 177, 10.1016/S1470-2045(14)71181-7 Remon, 2015, Sunitinib in patients with advanced thymoma and thymic carcinoma. Retrospective analysis from RYTHMIC database, J Thorac Oncol, 10 Tan, 2015, Efficacy and safety of an attenuated-dose sunitinib regimen in metastatic renal cell carcinoma: results from a prospective registry in Singapore, Clin Genitourin Cancer, 13, e285, 10.1016/j.clgc.2014.11.004 Pan, 2015, Sunitinib dosing schedule 2/1 improves tolerability, efficacy, and health-related quality of life in Chinese patients with metastatic renal cell carcinoma, Urol Oncol, 33, e9 Besse, 2015, Clinical activity of lucitanib in advanced thymic epithelial tumors, J Thorac Oncol, 10 Rautiola, 2014, Sunitinib-induced hypertension, neutropaenia and thrombocytopaenia as predictors of good prognosis in patients with metastatic renal cell carcinoma, BJU Int Gubens, 2015, A phase II study of saracatinib (AZD0530), a Src inhibitor, administered orally daily to patients with advanced thymic malignancies, Lung Cancer, 89, 57, 10.1016/j.lungcan.2015.04.008 Hong, 2013, A phase 1 study of gemcitabine combined with dasatinib in patients with advanced solid tumors, Invest New Drugs, 31, 918, 10.1007/s10637-012-9898-3 Besse, 2014, A phase II study of milciclib (PHA-848125AC) in patients (pts) with thymic carcinoma (TC), ASCO Meeting Abstr, 32, 7526 Guidoccio, 2011, Current role of 111In-DTPA-octreotide scintigraphy in diagnosis of thymic masses, Tumori, 97, 191, 10.1177/030089161109700210 Ferone, 1999, In vitro characterization of somatostatin receptors in the human thymus and effects of somatostatin and octreotide on cultured thymic epithelial cells, Endocrinology, 140, 373, 10.1210/endo.140.1.6398 Palmieri, 2002, Somatostatin analogs and prednisone in advanced refractory thymic tumors, Cancer, 94, 1414, 10.1002/cncr.10374 Loehrer, 2004, Eastern cooperative oncology group phase II trial. Octreotide alone or with prednisone in patients with advanced thymoma and thymic carcinoma: an Eastern cooperative oncology group phase II trial, J Clin Oncol, 22, 293, 10.1200/JCO.2004.02.047 Paz-Ares, 2013, PARAMOUNT: final overall survival results of the phase III study of maintenance pemetrexed versus placebo immediately after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer, J Clin Oncol, 31, 2895, 10.1200/JCO.2012.47.1102 Palmieri, 2015, Somatostatin analogs as maintenance therapy in heavily pretreated thymic epithelial tumors, ASCO Meeting Abstr, 33, 7581 Ottaviano, 2015, Effectiveness of somatostatin analogs plus prednisone in aggressive histotype and advanced stage of thymic epithelial tumors, ASCO Meeting Abstr, 33, 7582 Hanahan, 2011, Hallmarks of cancer: the next generation, Cell, 144, 646, 10.1016/j.cell.2011.02.013 Brahmer, 2015, Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer, N Engl J Med, 373, 123, 10.1056/NEJMoa1504627 Borghaei, 2015, Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer, N Engl J Med, 10.1056/NEJMoa1507643 Robert, 2015, Pembrolizumab versus ipilimumab in advanced melanoma, N Engl J Med, 372, 2521, 10.1056/NEJMoa1503093 Katsuya, 2015, Immunohistochemical status of PD-L1 in thymoma and thymic carcinoma, Lung Cancer, 88, 154, 10.1016/j.lungcan.2015.03.003 Naidoo, 2015, Defining the immunologic phenotype of thymic epithelial tumors, ASCO Meeting Abstr, 33, 7516 Padda, 2015, Diffuse high intensity PD-L1 staining in thymic epithelial tumors, J Thorac Oncol, 10, 500, 10.1097/JTO.0000000000000429 Brown, 2003, Blockade of programmed death-1 ligands on dendritic cells enhances T cell activation and cytokine production, J Immunol, 170, 1257, 10.4049/jimmunol.170.3.1257 Yokoyama, 2015, Programmed cell death 1 ligand (PD-L1) expression in thymoma, J Thorac Oncol, 10 Takumi, 2015, The clinicopathological significance of PD-L1 expression in thymoma, J Thorac Oncol, 10